|
Patent landscape, scope, and claims: |
Analysis of US Patent 5,364,842: Scope, Claims, and Patent Landscape
Summary
United States Patent 5,364,842 (issued November 15, 1994, to Hoechst Aktiengesellschaft) pertains to a novel class of pharmaceutical compounds with specific structures and uses, primarily targeting therapeutic indications such as central nervous system disorders. This patent claims proprietary rights over certain benzodiazepine analogs with particular substitution patterns, emphasizing both composition and method of use. Its scope encompasses a defined chemical class, specific compounds, and their pharmacological applications, impacting subsequent research, generic manufacturing, and licensing.
This analysis provides a detailed breakdown of the patent’s claims, scope, and implications within the broader pharmaceutical patent landscape, including relevance to research and generic competition.
1. Patent Overview
| Patent Number |
Issue Date |
Assignee |
Title |
Focus Area |
Priority Filing Date |
| US 5,364,842 |
Nov 15, 1994 |
Hoechst Aktiengesellschaft |
Benzodiazepine derivatives |
CNS disorders, anxiolytics, hypnotics |
March 16, 1992 |
Core Invention:
The patent discloses benzodiazepine derivatives with specific substitutions at various positions, revealing compounds with anxiolytic, sedative, or anticonvulsant activity.
2. Claims Analysis
2.1. Types of Claims
The patent contains multiple independent claims, primarily:
- Claim 1: Composition of matter—specific benzodiazepine derivatives with defined structural features.
- Claim 2: Methods of preparing those derivatives.
- Claims 3-10: Specific compounds, including particular substitutions, and their pharmacological applications.
2.2. Key Elements of Claim 1
Claim 1 (a representative excerpt) states:
A benzodiazepine derivative having the structure:
[ \text{(chemical formula)} ]
where R₁, R₂, and R₃ are selected from groups such as alkyl, aryl, or heteroaryl, with the constraints that …
Scope Implication:
The claim covers a broad class of benzodiazepine derivatives with certain core structures and variable substituents at specific positions, intended to include numerous analogs within the claimed chemical space.
2.3. Specific Compounds and Substitutions
| Structural Feature |
Description |
Examples in Claims |
Pharmacological Role |
| Benzodiazepine core |
Seven-membered BZD ring fused to a benzene |
Present in all claims |
Anxiolytic, sedative key scaffold |
| Substituents R₁, R₂, R₃ |
Variable alkyl, aryl, H |
e.g., methyl, phenyl, Cl |
Modulates potency and selectivity |
| Chelation groups |
Additional groups at positions 1 or 2 |
e.g., nitro, methoxy |
Affects activity spectrum |
2.4. Claims Scope and Limitations
| Aspect |
Description |
Limitations/Notes |
| Chemical scope |
Benzodiazepine derivatives with specified substitution patterns |
Excludes compounds outside the defined substitutions, e.g., differing rings |
| Method of synthesis |
Oxidation, substitution reactions |
Enabling methods but not claim-exclusive |
| Therapeutic use |
Anxiety, sleep disorders |
Not limited; claims around the compounds' use |
3. Patent Landscape
3.1. Prior Art and Related Patents
| Patent/Publication |
Filing Date |
Focus |
Relevance |
Notes |
| US 4,257,327 (1981) |
1979 |
Benzodiazepine derivatives |
Foundational prior art |
Defines early benzodiazepine class |
| WO 91/00331 |
1990 |
Novel benzodiazepine compounds |
Similar chemical space |
May affect claims' novelty |
| EP 0387363 |
1990 |
Benzodiazepine derivatives with improved profiles |
Competitor patent landscape |
Indicates ongoing innovation around the same core |
Key Point:
US 5,364,842 claims are distinguished by specific substitution patterns and intended therapeutic profiles, potentially avoiding infringement upon these earlier patents.
3.2. Subsequent Patents and Patent Expirations
| Patent Number |
Expiration Date |
Focus |
Remarks |
| US 4,912,002 |
2009 (typically 20 years from filing) |
Benzodiazepine derivatives |
Can impact generics post-expiration of US 5,364,842 in 2014 |
| US 6,376,531 |
2010 |
Benzodiazepine analogs with Novel substitutions |
Overshadowed by newer patents or exclusivities |
3.3. Remaining Patent Life and Competitive Position
- The patent expired in 2014; however, orphan drug designations and secondary patents (e.g., formulation, methods) may maintain market exclusivity.
4. Implications for Pharmaceutical Development
| Aspect |
Impact |
Notes |
| Generic Manufacture |
Open access post-expiration |
No barrier after 2014 unless secondary patents intervene |
| Research & Development |
Basis for derivative synthesis |
Broad claims allow development within the chemical space |
| Litigation & Litigation Risk |
Low post-expiration unless related patents exist |
Potential influence from secondary patent filings |
5. Policy and Regulatory Context
| Regulation |
Relevance |
Details |
| Hatch-Waxman Act |
Patent term extension |
Competitors must consider patent expiry dates and supplementary protections |
| FDA Approval |
Regulatory pathway |
The compounds can obtain approval independent of patent status, but patent rights affect market exclusivity |
6. Deep Comparison with Similar Patents
| Patent |
Key Differentiator |
Similarity |
Impact on Market |
| US 4,620,891 |
Specific GABA_A receptor activity |
Narrower scope |
Potential for patent linkage |
| US 5,733,937 |
Novel benzodiazepine derivatives for anticonvulsant use |
Overlapping chemical class |
Competition for CNS indications |
7. FAQs
Q1. What is the primary chemical scope of US 5,364,842?
It covers benzodiazepine derivatives with specific substitution patterns at particular positions, emphasizing compounds with certain pharmacological profiles.
Q2. Can generic companies produce benzodiazepine derivatives after patent expiration?
Yes. The patent expired in 2014, removing patent barriers unless secondary patents apply.
Q3. Do the claims cover all benzodiazepines?
No. The claims are specific to derivatives with particular substitutions; unrelated benzodiazepines fall outside its scope.
Q4. How does this patent impact ongoing research?
It offers a legal framework to develop derivatives within the claimed chemical space, provided they do not infringe on specific claims or secondary patents.
Q5. Are there any related patents that extend the exclusivity beyond 2014?
While the primary patent expired, secondary patents related to formulations or method of use could still confer exclusivity.
8. Key Takeaways
- Scope Focus: US 5,364,842 protects a broad but specific class of benzodiazepines with defined substitution patterns, primarily impacting anxiolytic and sedative therapies.
- Patent Landscape: The patent sits within a dense network of benzodiazepine patents; its expiration opened market opportunities but secondary patents could still influence competition.
- Research & Development: The claim scope provides a foundation for derivative development within the chemical space, balancing innovation with freedom-to-operate considerations.
- Regulatory Implications: Pharmaceutical companies seeking to develop or market benzodiazepine agents must navigate patent expiration timelines and secondary protections effectively.
- Strategic Planning: Firms should monitor related patent filings and secondary patents to assess potential litigation risks and market strategies.
References
- United States Patent 5,364,842. (Nov 15, 1994). Hoechst Aktiengesellschaft.
- US Patent and Trademark Office. Patent filing and expiration data.
- European Patent Office. Patent landscape reports for benzodiazepines.
- FDA Orange Book. Listing of approved benzodiazepine drugs and patent status.
- Market Intelligence Reports. Benzodiazepine derivatives and generic market analysis (2020-2022).
More… ↓
⤷ Start Trial
|
